Cargando…
Glucagon‐like peptide‐1 receptor agonists for type 2 diabetes: A rational drug development
Today, glucagon‐like peptide‐1 (GLP‐1) receptor agonists are established glucose‐lowering drugs used in the management of type 2 diabetes. Their development emerged from the understanding that a combined islet dysfunction comprising of impaired insulin secretion and exaggerated glucagon secretion is...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6400152/ https://www.ncbi.nlm.nih.gov/pubmed/30099845 http://dx.doi.org/10.1111/jdi.12911 |